The team led by Professor Chen Ling of the respiratory tract virus and infection team of the SKLRD worked with the team led by Professor Zhang Fuchun of the Eighth People’s Hospital of Guangzhou to derive monoclonal antibodies from convalescent patient targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model, and the result was published on the journal Emerging Microbes & Infections (IF: 6.032).

The research team applied the method of mono-cell PCR to derive three monoclonal anti-bodies with high neutralizing power and wide spectrum from the Zika virus infected patients migrant from South America to Guangzhou. In the neonatal mouse model, it can effectively treat the weight loss and neurological signs of the mice infected by virus. The high-dosage anti-body treatment group can completely clear the virus from the brain and spleen of the infected mice. The research indicates that the neutralizing anti-bodies derived from the Zika infected patients have the potential to serve as an anti-body drug to prevent and treat the infection of Zika virus.